ADARx Pharmaceuticals
Total Raised
$352.5MInvestors Count
17Funding, Valuation & Revenue
7 Fundings
ADARx Pharmaceuticals has raised $352.5M over 7 rounds.
ADARx Pharmaceuticals's latest funding round was a Series C for $200M on August 9, 2023.
Date | Round | Amount | Investors | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Revenue | Sources |
|---|---|---|---|---|---|---|
8/9/2023 | Series C | $200M | Bain Capital Life Sciences, TCG Crossover, Ascenta Capital, BlackRock, Commodore Capital, Cormorant Asset Management, HBM Healthcare Investments, Invus Group, Lilly Asia Ventures, Marshall Wace Asset Management, OrbiMed Advisors, Redmile Group, SR One, T. Rowe Price, Venrock Healthcare Capital Partners, and Vivo Capital | 1 | ||
1/20/2023 | Series B - II | |||||
8/17/2021 | Series B | |||||
5/21/2021 | Series A - III | |||||
11/17/2020 | Series A - II |
Date | 8/9/2023 | 1/20/2023 | 8/17/2021 | 5/21/2021 | 11/17/2020 |
|---|---|---|---|---|---|
Round | Series C | Series B - II | Series B | Series A - III | Series A - II |
Amount | $200M | ||||
Investors | Bain Capital Life Sciences, TCG Crossover, Ascenta Capital, BlackRock, Commodore Capital, Cormorant Asset Management, HBM Healthcare Investments, Invus Group, Lilly Asia Ventures, Marshall Wace Asset Management, OrbiMed Advisors, Redmile Group, SR One, T. Rowe Price, Venrock Healthcare Capital Partners, and Vivo Capital | ||||
Valuation | |||||
Revenue | |||||
Sources | 1 |
- Predict emerging trends
- See competitors' playbooks
- Stalk the smart money
- Identify tomorrow's challengers
- Spot growing industries
- Kill analyst data work
ADARx Pharmaceuticals Investors
17 Investors
ADARx Pharmaceuticals has 17 investors. OrbiMed Advisors invested in ADARx Pharmaceuticals's Series C funding round.
First funding | Last Funding | Investor | Rounds | Board Seats | Type | Location |
|---|---|---|---|---|---|---|
8/7/2020 | 8/9/2023 | 6 Series A, Series A - II (2020), Series A - III (2021), Series B (2021), Series B - II (2023), Series C (2023) | Venture Capital | New York | ||
8/17/2021 | 8/9/2023 | 3 Series B, Series B - II (2023), Series C (2023) | Venture Capital | Pennsylvania | ||
8/17/2021 | 8/9/2023 | 3 Series B, Series B - II (2023), Series C (2023) | Corporate Venture | China | ||
Venture Capital | Arkansas | |||||
Asset/Investment Management | New York |
First funding | 8/7/2020 | 8/17/2021 | 8/17/2021 | ||
|---|---|---|---|---|---|
Last Funding | 8/9/2023 | 8/9/2023 | 8/9/2023 | ||
Investor | |||||
Rounds | 6 Series A, Series A - II (2020), Series A - III (2021), Series B (2021), Series B - II (2023), Series C (2023) | 3 Series B, Series B - II (2023), Series C (2023) | 3 Series B, Series B - II (2023), Series C (2023) | ||
Board Seats | |||||
Type | Venture Capital | Venture Capital | Corporate Venture | Venture Capital | Asset/Investment Management |
Location | New York | Pennsylvania | China | Arkansas | New York |
- Predict emerging trends
- See competitors' playbooks
- Stalk the smart money
- Identify tomorrow's challengers
- Spot growing industries
- Kill analyst data work
Loading...